Tenet Healthcare (THC)
(Delayed Data from NYSE)
$165.21 USD
-3.31 (-1.96%)
Updated Nov 8, 2024 04:00 PM ET
After-Market: $165.15 -0.06 (-0.04%) 7:58 PM ET
1-Strong Buy of 5 1
A Value B Growth C Momentum A VGM
Price, Consensus and EPS Surprise
THC 165.21 -3.31(-1.96%)
Will THC be a Portfolio Killer in November?
Zacks Investment Research is releasing its prediction for THC based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for THC
The Zacks Rank Explained: How to Find Strong Buy Medical Stocks
Here's How Much a $1000 Investment in Tenet Healthcare Made 10 Years Ago Would Be Worth Today
THC: What are Zacks experts saying now?
Zacks Private Portfolio Services
HCA Healthcare Stock Up 12.7% in 6 Months: What Should Investors Do?
Pediatrix Medical Stock Soars 30.5% Since Q3 Earnings Beat
Are You a Momentum Investor? This 1 Stock Could Be the Perfect Pick
Other News for THC
Trump re-election: KeyBanc says watch these health and consumer stocks
Tenet Healthcare price target raised to $190 from $171 at Barclays
Barclays Reaffirms Their Buy Rating on Tenet Healthcare (THC)
Tenet Healthcare price target raised by $19 at Barclays, here's why
Hospital stocks could see negative impact under Trump